 |
 |

Endophthalmitis After Keratoprosthesis
Incidence, Bacterial Causes, and Risk Factors
Mahnaz Nouri, MD;
Hisao Terada, MD;
Eduardo C. Alfonso, MD;
C. Stephen Foster, MD;
Marlene L. Durand, MD;
Claes H. Dohlman, MD, PhD
Arch Ophthalmol. 2001;119:484-489.
Objectives To determine the rate of endophthalmitis in a group of patients with
keratoprostheses and to analyze possible risk factors.
Methods A total of 108 patient eyes, operated on between 1990 and 2000 with
double-plated keratoprostheses, were analyzed with regard to the surface flora,
the incidence and cause of bacterial endophthalmitis or sterile vitreitis,
the keratoprosthesis design, prophylactic antibiotics, concomitant immunosuppression,
and preoperative diagnosis.
Results Surveillance cultures were obtained from 30 uninfected eyes. The flora
was similar to that reported in the normal population and did not vary significantly
with time. Thirteen cases of bacterial endophthalmitis occurred 2 to 46 months
postoperatively in the patient population that had been followed up for 2
months to 17 years (average, 3 years 4 months). The incidence was 39% in 13
patients with Stevens-Johnson syndrome, 19% in 27 patients with ocular cicatricial
pemphigoid, and 7% in 28 patients with ocular burns. Only 1 of the other 40
cases (consisting mostly of repeated graft failures in noncicatrizing conditions)
developed endophthalmitis; this patient had a filtering bleb. All endophthalmitis
pathogens were gram positive: Streptococcus pneumoniae,
23%; other streptococci, 39%; Staphylococcus aureus,
23%; and Staphylococcus epidermidis, 15%.
Conclusions The most important risk factor for endophthalmitis after these keratoprostheses
was found to be preoperative diagnosis. The rate of infection was very high
in Stevens-Johnson syndrome and ocular cicatricial pemphigoid, moderate in
chemical burns, and low in noncicatrizing corneal disease.
From the Departments of Ophthalmology, Massachusetts Eye and Ear Infirmary,
and Harvard Medical School, Boston (Drs Nouri, Terada, Foster, Durand, and
Dohlman); and Bascom Palmer Eye Institute and University of Miami School of
Medicine, Miami, Fla (Dr Alfonso). The authors have no proprietary interest
in any device described in this article.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(4):631.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Modified Osteo-odonto-keratoprosthesis for Treatment of Corneal Blindness: Long-term Anatomical and Functional Outcomes in 181 Cases
Falcinelli et al.
Arch Ophthalmol 2005;123:1319-1329.
ABSTRACT
| FULL TEXT
Biological Response to a SupraDescemetic Synthetic Cornea in Rabbits
Stoiber et al.
Arch Ophthalmol 2004;122:1850-1855.
ABSTRACT
| FULL TEXT
Five year follow up of biocolonisable microporous fluorocarbon haptic (BIOKOP) keratoprosthesis implantation in patients with high risk of corneal graft failure
Alio et al.
Br J Ophthalmol 2004;88:1585-1589.
ABSTRACT
| FULL TEXT
Seoul-Type Keratoprosthesis: Preliminary Results of the First 7 Human Cases
Kim et al.
Arch Ophthalmol 2002;120:761-766.
ABSTRACT
| FULL TEXT
Management of Vitreoretinal Complications in Eyes With Permanent Keratoprosthesis
Ray et al.
Arch Ophthalmol 2002;120:559-566.
ABSTRACT
| FULL TEXT
|